AM-Pharma, BV: Series C $36M

Posted in I - Series C, Q - 2Q08, R - INTERNATIONAL, X - Autoimmune, X - Renal

AM-Pharma (Netherlands) biopharmaceutical company developing endogenous proteins and peptides to combat acute renal failure, ulcerative colitis and hospital acquired infections, closed a $36M Series C financing. Participants include Forbion Capital Partners and Inventages Venture Capital.

Nov

2008

Quark Pharmaceuticals, Inc.: Series B $27M

Posted in I - Series B, Q - 2Q08, R - WEST, X - Opthalmology, X - RNAi, X - Renal

Quark Pharmaceuticals (Fremont, CA) development-stage pharmaceutical company focused on discovering and developing novel RNAi therapeutics, closed a $27M Series B financing. Participants include SBI Investment Co.

Nov

2008

Stromedix, Inc.: Series B $25M

Posted in I - Series B, Q - 2Q08, R - NORTH EAST, X - Fibrosis, X - Oncology, X - Organ Failure, X - Renal

Stromedix (Cambridge, MA) development-stage biotechnology company focused on therapies for fibrosis, closed a $25M Series B financing. Participants include New Leaf Venture Partners, Bessemer Venture Partners, Red Abbey Venture Partners, Atlas Venture and Frazier Healthcare Ventures.

Feb

2008

Pervasis Therapeutics, Inc.: Series B $9.75M

Posted in I - Series B, Q - 1Q08, R - NORTH EAST, X - Renal

Pervasis Therapeutics (Cambridge, MA) is working to regulate vascular repair and restore natural blood flow to critical organs in end-stage renal disease closed a $9.75M Series B financing. Participants include Flagship Venture Partners, Polaris Venture Partners, Highland Capital Partners, and Musket Research Associates.

Next Entries »

to top of page...